Study with Jusvinza in patients with RA in Holguín in its final stage

The expanded intervention study with Jusvinza in patients with rheumatoid arthritis (RA) with moderate to severe activity is scheduled to culminate next March in the eastern provinces and Camagüey, whose clinical site is the Lucía Iñiguez Landín hospital, in Holguín.

Dr. Alberto Alberteris Rodríguez, Second Degree specialist in Rheumatology and Researcher responsible for the study in Holguín, highlighted that on February 17, the application of the last dose of the product began to the first group of people included who since last eight September began to receive Jusvinza periodically.

According to information published on the Hospital’s Facebook profile, it is expected that in the next month a comprehensive evaluation of the results of the study will be carried out on the patients, after 28 weeks of starting treatment.

Jusvinza is a product of Cuban biotechnology, developed by the Center for Genetic Engineering and Biotechnology (CIGB), whose use in patients with RA has demonstrated effectiveness, due to its anti-inflammatory effect and ability to modulate the immune response without causing immunosuppression in the patient.

The specialist assures that "so far the results are encouraging, which is why the use of this medication could improve the quality of life of patients with the disease."

(RA) affects between one and three percent of the world's population and tends to severely affect the function of the main joints and be accompanied by systemic manifestations, which frequently lead to a certain degree of disability in people affected, according to an article published in the Cuban Journal of Rheumatology.